Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Acerus Pharmaceuticals Corp ASPCQ

Acerus Pharmaceuticals Corp is a specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of branded products that improve patient experience, with a primary focus on the field of men's health. Its foundational product includes NATESTO, a testosterone therapy based on nasal gel technology. The company commercializes its products via its salesforce in the United States and Canada, and through a global network of licensed distributors in other territories.


OTCPK:ASPCQ - Post by User

Comment by PitchinPennieson Jul 05, 2022 6:06pm
115 Views
Post# 34803468

RE:RE:A new poem to commemorate the Acerus Annual General Meeting

RE:RE:A new poem to commemorate the Acerus Annual General Meeting@Contrarian: I'm looking at the Acerus trade volumes since the deal with Serenity Pharmaceuticals was announced in March. Essentially, ASP trading flatlined at a point just after the share consolidation and before the Annual General Meeting. Today's volume of 152 shares worth around Cdn$450.00 is typical of the past few weeks' sessions. That's beyond curious, and seems outright bizarre. 

The Serenity deal was structured as a share-swap, with Serenity's shareholders due to receive 804 million ASP shares. However, ASP share value has fallen by 60 per cent since the deal was announced on Feb. 28 of this year. No doubt that Dr. Samuel Herschkowitz, boss of Serenity, is far from serene at this moment. Is it a coincidence that Acerus is dragging its heels on the US$6 million upfront payment due to Serenity, which is now overdue?

Ian's sudden contribution of $2.1 million into the Acerus current account was just intended to keep the lights on for another month or two. The shoe that is about to drop will come when they announce the takeover deal is a no-go. If that occurs, stand by and prepare to watch one more  bloodbath. 
<< Previous
Bullboard Posts
Next >>